Legend Biotech (LEGN) has released an update.
Legend Biotech’s CARVYKTI therapy, featured at the American Society of Hematology meeting, shows promising results in increasing minimal residual disease negativity in multiple myeloma patients. This breakthrough could position CARVYKTI as a transformative treatment option, offering new hope to those resistant to standard therapies. The therapy has already secured FDA and European approvals, expanding its global reach and impact.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Computer (SMCI) Says Special Committee Found No Evidence of Fraud
- Netflix’s France and Netherlands Offices Raided for Possible Tax Fraud
- Class Action Lawsuit Against Bumble Inc. (NASDAQ:BMBL)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
